A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/08/2001	CA2407317A1 Dihydropyridine compounds and methods of use
11/08/2001	CA2407292A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	CA2407285A1 (+) naloxone and epinephrine combination therapy
11/08/2001	CA2407235A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
11/08/2001	CA2407189A1 New gamma selective retinoids
11/08/2001	CA2407134A1 Cancer therapy
11/08/2001	CA2407132A1 Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
11/08/2001	CA2407129A1 Medicinal formulation comprising pioglitazone
11/08/2001	CA2405832A1 P-(sulfonyl)aryl and heteroaryls
11/08/2001	CA2405745A1 New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments
11/08/2001	CA2405614A1 Chromenylmethyl pyrimidinediamines as antibacterial agents
11/08/2001	CA2405611A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	CA2405607A1 Pyrimidinyl methyl indole derivatives with antibacterial activity
11/08/2001	CA2404936A1 (5r)-(methylamino)-5,6-dihydro-4h-imidazo¬4,5,1-ij\|quinoline-2(1h)-thione
11/08/2001	CA2377629A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/07/2001	EP1152243A1 DIagnosis of Sjögren's syndrome, systemic lupus erythematosis, and scleroderma via detection of anti-retroviral antibodies
11/07/2001	EP1152061A1 Development of method for screening physiologically active pyrrole imidazole derivative
11/07/2001	EP1152056A1 Method for modifying genetic characteristics of an organism
11/07/2001	EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001	EP1152009A1 Novel nucleosides and oligonucleotide analogues
11/07/2001	EP1151998A1 Estrogen agonists/antagonists
11/07/2001	EP1151995A1 Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol
11/07/2001	EP1151990A1 Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
11/07/2001	EP1151753A1 Preventive and therapeutic agents for arteriosclerosis
11/07/2001	EP1151752A2 Method for inhibiting bone resorption
11/07/2001	EP1151751A1 Cataplasms containing vitamin c or its derivative
11/07/2001	EP1151750A1 Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds
11/07/2001	EP1151745A1 Water-in-oil emulsion and its use in cosmetics
11/07/2001	EP1151741A1 Microcapsules with an aqueous core containing at least an active water-soluble cosmetic or dermatologic ingredient and cosmetic or dermatologic compositions containing these microcapsules
11/07/2001	EP1151295A1 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
11/07/2001	EP1151131A1 Process for the preparation of pseudomonic acid a antibiotic by microbiological method
11/07/2001	EP1151129A2 Methods of making compounds
11/07/2001	EP1151124A1 Gene repair involving in vivo excision of targeting dna
11/07/2001	EP1151113A2 Human peptidases
11/07/2001	EP1151099A1 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
11/07/2001	EP1151095A1 Polypeptide variants with raised heparin-binding capacity
11/07/2001	EP1151092A1 Inhibiting formation of atherosclerotic lesions
11/07/2001	EP1151089A1 Catalytic molecules
11/07/2001	EP1151067A1 Process of converting rendered triglyceride oil from marine sources into bland, stable oil
11/07/2001	EP1151009A2 Antimicrobial/endotoxin neutralizing polypeptide
11/07/2001	EP1150997A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
11/07/2001	EP1150996A1 New amidinobenzylamine derivatives and their use as thrombin inhibitors
11/07/2001	EP1150994A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
11/07/2001	EP1150993A1 Unsaturated cholestane derivatives and their use for the preparation of meiosis regulating medicaments
11/07/2001	EP1150991A2 Compositions for treating inflammatory response
11/07/2001	EP1150990A1 Erythromycin a compounds and process for preparing the same
11/07/2001	EP1150988A1 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
11/07/2001	EP1150983A1 Triazolo-pyridazine derivatives as ligands for gaba receptors
11/07/2001	EP1150982A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a)
11/07/2001	EP1150981A1 Therapeutic nucleoside compound
11/07/2001	EP1150980A2 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
11/07/2001	EP1150979A1 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
11/07/2001	EP1150978A1 Carbamate derivatives of diaryl 1,3,4-oxadiazolone
11/07/2001	EP1150977A1 Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
11/07/2001	EP1150976A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
11/07/2001	EP1150974A1 Heterocyclic derivatives as inhibitors of factor xa
11/07/2001	EP1150973A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
11/07/2001	EP1150972A1 Triazole and tetrazole derivatives, and their therapeutic use
11/07/2001	EP1150971A1 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
11/07/2001	EP1150970A1 (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
11/07/2001	EP1150969A1 Alpha-azacyclomethyl quinoline derivatives for treating urinary incontinence
11/07/2001	EP1150965A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
11/07/2001	EP1150963A1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
11/07/2001	EP1150961A1 Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
11/07/2001	EP1150960A1 Polymorphic crystalline forms of celecoxib
11/07/2001	EP1150959A1 Solid-state form of celecoxib having enhanced bioavailability
11/07/2001	EP1150958A1 Substituted pyrazole carboxylic acids used to combat anaemias
11/07/2001	EP1150957A1 N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
11/07/2001	EP1150956A1 Non-nucleoside reverse transcriptase inhibitors
11/07/2001	EP1150954A1 Anti-imflammatory indole derivatives
11/07/2001	EP1150953A1 Indole derivatives and their use as mcp-1 receptor antagonists
11/07/2001	EP1150952A1 Indole derivatives and their use as mcp-1 receptor antagonists
11/07/2001	EP1150950A2 Anthranilic acid derivatives
11/07/2001	EP1150948A1 ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa
11/07/2001	EP1150946A1 Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
11/07/2001	EP1150939A1 Nephronin: a series of compounds for treatment of infectious diseases and cancer
11/07/2001	EP1150746A2 The use of 4-h-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
11/07/2001	EP1150728A1 Methods and compositions for use in perfusion applications
11/07/2001	EP1150715A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
11/07/2001	EP1150708A2 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
11/07/2001	EP1150707A1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS
11/07/2001	EP1150706A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response
11/07/2001	EP1150695A2 Herbal supplement for increased muscle strength and endurance for athletes
11/07/2001	EP1150692A2 Means for regulating hematopoietic differentiation
11/07/2001	EP1150691A2 Novel antisense inhibition of rad51
11/07/2001	EP1150690A1 Chemical compounds
11/07/2001	EP1150689A1 Chemical compounds
11/07/2001	EP1150687A2 Methods for anti-tumor therapy
11/07/2001	EP1150686A1 Directly compressible matrix for controlled release of single daily doses of clarithromycin
11/07/2001	EP1150685A1 Phosphocholine surfactants and their use
11/07/2001	EP1150684A1 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
11/07/2001	EP1150683A1 Utilization of dienogest in high doses
11/07/2001	EP1150682A2 UBIQUINONE Qn FOR THE TREATMENT OF PAINS
11/07/2001	EP1150681A2 Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
11/07/2001	EP1150680A1 Use of moxonidine for postmyocardial infarction treatment
11/07/2001	EP1150679A1 Use of cholesterol-lowering agent
11/07/2001	EP1150678A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
11/07/2001	EP1150677A1 New pharmaceutical formulation
11/07/2001	EP1150676A1 Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
11/07/2001	EP1150675A1 A transdermal composition of an antivomiting agent and a preparation containing the same

1 ... 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 5989 5990 5991 5992 5993 ... 7860